Public market insider net buying at Advanz Pharma (ADVZ)

Public market insider net buying at Advanz Pharma (T:ADVZ)

Solus Alternative Asset Management LP, a 10% Holder, acquired 533,100 Limited Voting Shares on a control or direction basis for registered holder Certain funds and accounts managed by Solus Alternative Asset Management LP and/or subsidiaries thereof at prices ranging from $19.248 to $24.545 between March 28th, 2019 and April 1st, 2019. This represents a $10,689,213 net investment into the company's shares and an account share holdings change of 6.4%.

Advanz Pharma is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Advanz Pharma Corp, formerly Concordia International Corp, is a Canada-based pharmaceutical company. It is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. The Company is focused on investing in product portfolio with aim to optimize healthcare treatment. The Company does this through product acquisitions, in-licensing opportunities, product development and alliances worldwide. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products and operates facilities in various locations, including Bridgetown, Barbados; London, England; Mumbai, India, and Mississauga, Canada. Advanz Pharma Corp. (ADVZ) has below median officer and director direct ownership compared to its mid-cap peers in the market, based on our estimate using SEDI data. According to regulatory filings yesterday, one insider has invested a net amount of $10,689,213.